SCYNEXIS (SCYX) Projected to Post Earnings on Thursday

SCYNEXIS (NASDAQ:SCYX) is projected to release its earnings data before the market opens on Thursday, March 27th. Analysts expect SCYNEXIS to post earnings of ($0.02) per share and revenue of $10.19 million for the quarter.

SCYNEXIS (NASDAQ:SCYX) last released its earnings results on Wednesday, March 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.13. The company had revenue of $0.98 million for the quarter. SCYNEXIS had a negative net margin of 425.41% and a negative return on equity of 66.21%.

SCYNEXIS Trading Down 1.0 %

Shares of NASDAQ SCYX opened at $1.03 on Wednesday. The stock has a market cap of $40.15 million, a P/E ratio of -1.39 and a beta of 1.67. The business’s fifty day simple moving average is $1.06 and its 200-day simple moving average is $1.23. SCYNEXIS has a 12-month low of $0.82 and a 12-month high of $3.07.

Wall Street Analysts Forecast Growth

Separately, StockNews.com cut SCYNEXIS from a “hold” rating to a “sell” rating in a research report on Saturday.

About SCYNEXIS

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.